Capricor Therapeutics Inc. is facing a class action lawsuit filed on behalf of investors who experienced financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, and claims that Capricor provided misleading information regarding the prospects of obtaining a Biologics License Application for its lead cell therapy candidate, deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy. The U.S. Food and Drug Administration had issued a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and outstanding issues related to Chemistry, Manufacturing, and Controls. Following this announcement, Capricor's stock price dropped significantly. The lawsuit alleges that the company failed to disclose material adverse facts about its Phase 2 HOPE-2 trial study, thereby misleading investors. The legal proceedings are being handled by Levi & Korsinsky, a firm with extensive experience in securities litigation.